Hematologic parameters from BERKAA and BERKSS mice treated with rivaroxaban (0.4 mg/g chow) or placebo chow
| Variable . | AA/Con . | AA/Riv . | SS/Con . | SS/Riv . |
|---|---|---|---|---|
| RBC (106/µL) | 8.0 ± 0.7 | 8.2 ± 0.9 | 5.1 ± 0.7*** | 4.7 ± 0.8*** |
| Hematocrit (%) | 32.7 ± 3.3 | 33.1 ± 3.7 | 22.5 ± 3.8*** | 22.0 ± 3.7*** |
| RDW (%) | 18.3 ± 1.0 | 18.7 ± 2.1 | 28.6 ± 2.1*** | 29.1 ± 2.8*** |
| WBC (103/µL) | 4.1 ± 2.1 | 3.92 ± 1.1 | 39.1± 10.7*** | 39.3 ± 13.1*** |
| Neutrophil (103/µL) | 0.9 ± 0.7 | 0.9 ± 0.4 | 3.9 ± 2.1*** | 3.5 ± 2.3*** |
| Lymphocyte (103/µL) | 3.0 ± 1.8 | 2.9 ± 0.9 | 33.1 ± 8.6*** | 33.6 ± 10.1*** |
| Monocyte (103/µL) | 0.2 ± 0.1 | 0.2 ± 0.1 | 2.0 ± 0.7*** | 2.2 ± 1.2*** |
| Platelet (103/µL) | 652 ± 85 | 626 ± 117 | 709 ± 144 | 688 ± 85 |
| Variable . | AA/Con . | AA/Riv . | SS/Con . | SS/Riv . |
|---|---|---|---|---|
| RBC (106/µL) | 8.0 ± 0.7 | 8.2 ± 0.9 | 5.1 ± 0.7*** | 4.7 ± 0.8*** |
| Hematocrit (%) | 32.7 ± 3.3 | 33.1 ± 3.7 | 22.5 ± 3.8*** | 22.0 ± 3.7*** |
| RDW (%) | 18.3 ± 1.0 | 18.7 ± 2.1 | 28.6 ± 2.1*** | 29.1 ± 2.8*** |
| WBC (103/µL) | 4.1 ± 2.1 | 3.92 ± 1.1 | 39.1± 10.7*** | 39.3 ± 13.1*** |
| Neutrophil (103/µL) | 0.9 ± 0.7 | 0.9 ± 0.4 | 3.9 ± 2.1*** | 3.5 ± 2.3*** |
| Lymphocyte (103/µL) | 3.0 ± 1.8 | 2.9 ± 0.9 | 33.1 ± 8.6*** | 33.6 ± 10.1*** |
| Monocyte (103/µL) | 0.2 ± 0.1 | 0.2 ± 0.1 | 2.0 ± 0.7*** | 2.2 ± 1.2*** |
| Platelet (103/µL) | 652 ± 85 | 626 ± 117 | 709 ± 144 | 688 ± 85 |
Asterisks indicate significant difference compared with BERKAA mice within the same treatment (***P < .001). There were no statistically significant differences in any parameters between Riv and Con within BERKAA or BERKSS mice.
Con, control placebo; RDW, red cell distribution width; Riv, rivaroxaban; WBC, white blood cell.